CytomX Therapeutics

CytomX is unlocking the potential of antibody therapeutics in oncology by developing a novel therapeutic antibody class of highly targeted Probody therapeutics. The Company's Probody Platform allows to design drugs that selectively activate in the tumor microenvironment while reducing drug activity in healthy tissue and in circulation. This ability to localize therapeutic effects to the tumor reduces systemic toxicity, with potential for safer and more effective therapies for a broad array of validated and previously inaccessible oncology targets. Driven by a vision to transform patient lives, CytomX is an advancing multiple Probody cancer immunotherapies and Probody drug conjugates toward clinical investigation, while also applying its technology to bispecific T-cell engaging antibodies and ProCAR-NK cell therapies.
Company Growth (employees)
Type
Public
HQ
South San Francisco, US
Founded
2008
Size (employees)
78 (est)
Website
cytomx.com
CytomX Therapeutics was founded in 2008 and is headquartered in South San Francisco, US

CytomX Therapeutics Office Locations

CytomX Therapeutics has an office in South San Francisco
South San Francisco, US (HQ)
100 343 Oyster Point Blvd
Show all (1)

CytomX Therapeutics Financials and Metrics

CytomX Therapeutics Financials

CytomX Therapeutics's revenue was reported to be $15 m in FY, 2016
USD

Revenue (Q3, 2017)

23.7 m

Net income (Q3, 2017)

(10.2 m)

EBIT (Q3, 2017)

(11 m)

Market capitalization (22-Dec-2017)

838.3 m
CytomX Therapeutics's current market capitalization is $838.3 m.
USDFY, 2015FY, 2016

Revenue

7.7 m15 m

Revenue growth, %

95%

EBIT

(33.2 m)(59.6 m)

EBIT margin, %

(431%)(396%)
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

1.9 m1.8 m2.5 m2.8 m11.2 m8.3 m23.7 m

R&D expense

9.2 m13.4 m12.7 m13.3 m14.6 m28.1 m

General and administrative expense

4.1 m5 m4.6 m5 m5.7 m6 m

Operating expense total

13.2 m18.4 m17.4 m18.4 m20.3 m34.1 m35.2 m
USDFY, 2015FY, 2016

Cash

59.8 m104.6 m

Accounts Receivable

744 k2.2 m

Inventories

2.3 m3.9 m

Current Assets

189.8 m188.1 m
USDQ3, 2017

Accounts Receivable

40.2 m

Inventories

4.8 m

Accounts Payable

2.9 m
    USDFY, 2015FY, 2016

    Net Income

    (35.4 m)(58.9 m)

    Depreciation and Amortization

    1.2 m1.7 m

    Accounts Receivable

    1.1 m(1.8 m)

    Accounts Payable

    2.9 m1.8 m
    USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

    Net Income

    (11.9 m)(16 m)(14.2 m)(14.7 m)(8.3 m)(10.2 m)

    Accounts Receivable

    406 k316 k285 k240 k213 k158 k40.2 m

    Inventories

    4.8 m

    Accounts Payable

    2.7 m5 m1.4 m517 k3.7 m6.4 m2.9 m
      USDY, 2017

      Revenue/Employee

      303.4 k
      Show all financial metrics

      CytomX Therapeutics Operating Metrics

      FY, 2016

      Phase I Trials

      1

      Phase Preclinical

      4

      Patents (US)

      13

      Patents (foreign)

      4
      Show all operating metrics

      CytomX Therapeutics Market Value History

      CytomX Therapeutics's Web-traffic and Trends

      CytomX Therapeutics Online and Social Media Presence

      CytomX Therapeutics Company Life and Culture

      You may also be interested in